La presión para tratar el tratamiento.

Education debate: clinical diagnostic reasoning.

Internal medicine journal·2011

An evolution-based hypothesis on the origin and mechanisms of autoimmune disease.

Immunology and cell biology·1998

Species variation in the metabolism of 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one to its 3,4-dihydrodiol, the proximate carcinogen.

Carcinogenesis·1995

The presence of a trifluoromethyl rather than a methyl substituent in the bay-region greatly decreases the DNA-binding and tumour-initiating activity of the cyclopenta[alpha]phenanthren-17-ones.

Carcinogenesis·1995

CYP1 induction, binding to the hepatic aromatic hydrocarbon receptor and mutagenicity of a series of 11-alkoxy cyclopenta[a]phenanthren-17-ones: a structure activity relationship.

Toxicology·1995

The influence of dihydrodiol conformation on the metabolic activation of cyclopenta[a]phenanthrenes.

Toxicology letters·1995

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Mutation-Induced Pocket Deactivation: How Ser353/Pro245 Alters KCa2.2 vs. KCa3.1 Ligand Selectivity.

Archiv der Pharmazie·2026

A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.

Science translational medicine·2026

Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus.

Diabetes, obesity & metabolism·2026

Ameliorative Effects of Spirulina platensis Protein Hydrolysate on Oxidative Stress and Dyslipidemia in Model Animal.

Foods (Basel, Switzerland)·2026

Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.

JAMA network open·2026

Videos de Experimentos Relacionados

La presión para tratar el tratamiento

Videos de Conceptos Relacionados

Education debate: clinical diagnostic reasoning.

An evolution-based hypothesis on the origin and mechanisms of autoimmune disease.

Species variation in the metabolism of 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one to its 3,4-dihydrodiol, the proximate carcinogen.

The presence of a trifluoromethyl rather than a methyl substituent in the bay-region greatly decreases the DNA-binding and tumour-initiating activity of the cyclopenta[alpha]phenanthren-17-ones.

CYP1 induction, binding to the hepatic aromatic hydrocarbon receptor and mutagenicity of a series of 11-alkoxy cyclopenta[a]phenanthren-17-ones: a structure activity relationship.

The influence of dihydrodiol conformation on the metabolic activation of cyclopenta[a]phenanthrenes.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Mutation-Induced Pocket Deactivation: How Ser353/Pro245 Alters KCa2.2 vs. KCa3.1 Ligand Selectivity.

A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.

Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus.

Ameliorative Effects of Spirulina platensis Protein Hydrolysate on Oxidative Stress and Dyslipidemia in Model Animal.

Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.

Videos de Experimentos Relacionados

La presión para tratar el tratamiento

Videos de Conceptos Relacionados

Artículos Relacionados